HCTI vs ISPC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HCTI presents a classic value trap scenario, characterized by a stable Piotroski F-Score of 4/9 but catastrophic price action and fundamental decay. While the company shows strong top-line revenue growth of 44.6%, it is coupled with a disastrous ROE of -183% and an operating margin of -74.26%. The extreme discrepancy between the 52-week high ($7470) and current price ($2.40) indicates a total collapse in investor confidence or a massive corporate restructuring. Despite low debt and a healthy current ratio, the lack of profitability and negative earnings surprises make this a high-risk speculative asset.
The company is in severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a total absence of a viable Altman Z-Score. Revenue has collapsed by 96.50% year-over-year, while operating margins have plummeted to -5192.87%, indicating a complete breakdown of the business model. With a 5-year price decline of 99.9% and a technical trend score of 0/100, the stock is in a terminal bearish phase. Despite a low debt-to-equity ratio, the lack of top-line growth and extreme losses make the equity highly speculative and high-risk.
Compare Another Pair
Related Comparisons
HCTI vs ISPC: Head-to-Head Comparison
This page compares Healthcare Triangle, Inc. (HCTI) and iSpecimen Inc. (ISPC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.